tofacitinib + midazolam

A **combination of tofacitinib**, an oral Janus kinase inhibitor used primarily in the treatment of rheumatoid arthritis and other autoimmune conditions, and **midazolam**, a short-acting benzodiazepine used for sedation, anesthesia, and the treatment of acute seizures. This combination is not a marketed pharmaceutical product; rather, it is used in clinical pharmacokinetic drug–drug interaction studies. Tofacitinib does **not significantly affect the pharmacokinetics of midazolam**, indicating a lack of clinically relevant CYP3A4 inhibition or induction. Both drugs are small molecules: tofacitinib works by inhibiting Janus kinases (mainly JAK1 and JAK3), which downregulates immune signaling, while midazolam acts as a positive allosteric modulator at the gamma-aminobutyric acid type A (GABA-A) receptor to enhance inhibitory neurotransmission[1].

Brand names

tofacitinib + midazolam

Other names

tofacitinib plus midazolam